A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA) (OPAL)

Principal Investigator

Prof Laurent Servais

Contact us

Email: childrensresearch@ouh.nhs.uk

IRAS number

1012301